Neurocrine Biosciences, Inc.
MX ˙ BMV ˙ US64125C1099
SecurityMX:NBIX / Neurocrine Biosciences, Inc.
InstitutionRenaissance Technologies Llc
ManagerJames Simons
Latest Disclosed Ownership2,418,897 shares
Latest Disclosed Value $ 318,665,491
Renaissance Technologies Llc reports 8.04% increase in ownership of NBIX / Neurocrine Biosciences, Inc.

On May 14, 2026 - Renaissance Technologies Llc filed a 13F-HR form disclosing ownership of 2,418,897 shares of Neurocrine Biosciences, Inc. (MX:NBIX) valued at $318,665,491 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 12, 2026 disclosing 2,238,797 shares of Neurocrine Biosciences, Inc.. This represents a change in shares of 8.04% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-14 2026-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 2,418,897 180,100 8.04 318,665 0.36 0.4985
2026-02-12 2025-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 2,238,797 -179,500 -7.42 317,529 -6.47 0.4926
2025-11-13 2025-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 2,418,297 51,900 2.19 339,481 14.14 0.4481
2025-08-13 2025-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 2,366,397 -136,300 -5.45 297,432 7.45 0.3957
2025-05-14 2025-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 2,502,697 13,300 0.53 276,798 -18.54 0.4189
2025-02-13 2024-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 2,489,397 -85,149 -3.31 339,803 14.55 0.5030
2024-11-13 2024-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 2,574,546 106,400 4.31 296,639 -12.70 0.4461
2024-08-09 2024-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 2,468,146 216,500 9.62 339,790 109,509.35 0.5763
2024-05-13 2024-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 2,251,646 263,100 13.23 311 18.32 0.4881
2024-02-13 2023-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 1,988,546 398,382 25.05 262 47.19 0.4055
2023-11-14 2023-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 1,590,164 -53,238 -3.24 179 15.58 0.3050
2023-08-11 2023-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 1,643,402 -303,662 -15.60 155 -21.83 0.2233
2023-05-12 2023-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 1,947,064 333,400 20.66 197 2.60 0.2615
2023-02-13 2022-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 1,613,664 171,200 11.87 193 -99.87 0.2637
2022-11-14 2022-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 1,442,464 -6,559 -0.45 153,204 8.46 0.2167
2022-08-12 2022-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 1,449,023 168,900 13.19 141,251 17.70 0.1672
2022-05-13 2022-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 1,280,123 -143,541 -10.08 120,012 -1.02 0.1408
2022-02-11 2021-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 1,423,664 67,700 4.99 121,253 -6.77 0.1508
2021-11-12 2021-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 1,355,964 113,241 9.11 130,051 7.53 0.1680
2021-08-13 2021-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 1,242,723 -155,141 -11.10 120,942 -11.03 0.1510
2021-05-13 2021-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 1,397,864 -409,327 -22.65 135,942 -21.52 0.1691
2021-02-10 2020-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 1,807,191 -342,273 -15.92 173,219 -16.19 0.1881
2020-11-13 2020-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 2,149,464 664,700 44.77 206,692 14.11 0.2064
2020-08-13 2020-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 1,484,764 765,382 106.39 181,141 190.93 0.1564
2020-05-14 2020-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 719,382 -19,790 -2.68 62,263 -21.64 0.0605
2020-02-13 2019-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 739,172 735,272 18,853.13 79,454 22,536.47 0.0611
2019-11-13 2019-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 3,900 -11,341 -74.41 351 -72.73 0.0003
2019-08-12 2019-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 15,241 -212,700 -93.31 1,287 -93.59 0.0011
2019-05-14 2019-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 227,941 152,100 200.55 20,082 270.79 0.0183
2019-02-12 2018-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 75,841 75,841 -66.73 5,416 -73.03 0.0059
2018-11-13 2018-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 0 -162,341 -100.00 0 -100.00
2018-08-13 2018-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 162,341 0 0.00 13,463 0.00 0.0147
2018-05-14 2018-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 162,341 -224,900 -58.08 13,463 -55.19 0.0147
2018-02-13 2017-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 387,241 387,241 30,046 0.0331
2016-02-11 2015-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 0 -130,641 -100.00 0 -100.00
2015-11-12 2015-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 130,641 130,641 5,198 0.0124
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.